Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-06-14 pm EDT			5-day change	1st Jan Change
41.2 ^USD	-0.68%		-0.68%	-19.70%

Jun. 14	Bristol Myers: FDA approval for treatment	CF
Jun. 13	Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	MT

R. Sanders Williams to Leave Board of Directors of Bristol-Myers Squibb Company

January 25, 2013 at 04:27 pm EST

On January 22, 2013, R. Sanders Williams, M.D. notified Bristol-Myers Squibb Company that he will not stand for re-election to the Board of Directors at the 2013 Annual Meeting of Stockholders, which is expected to be held in May 2013.

Latest news about Bristol-Myers Squibb Company

Bristol Myers: FDA approval for treatment	Jun. 14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	Jun. 13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	Jun. 13	DJ
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	Jun. 12	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	Jun. 12	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	Jun. 12	CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	Jun. 11
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	Jun. 10	MT
Geron shares surge after U.S. FDA approves blood disorder drug	Jun. 07	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	Jun. 05	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	Jun. 05	CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	Jun. 04	MT
Bristol Myers: positive results in liver cancer	Jun. 04	CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	Jun. 04	CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company	Jun. 03	CI
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	Jun. 03	MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting	Jun. 03	CI
Bristol Myers: presents advances in lung cancer	Jun. 03	CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	Jun. 03	CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	Jun. 02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	Jun. 02	RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	Jun. 01	CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	May. 30	MT
Bristol Myers: FDA approval for Breyanzi	May. 30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	May. 30	RE

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

11:30pm - European Hematology Association Meeting - Abstract No #S208

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.2 USD

Average target price

53.19 USD

Spread / Average Target

+29.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.70%	83.52B
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B

Other Pharmaceuticals

Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

R. Sanders Williams to Leave Board of Directors of Bristol-Myers Squibb Company

EPS Revisions